


**AMENDMENTS TO THE CLAIMS:**

*This listing of the claims below will replace all prior versions and listing of claims in this application.*

Claim 1 (Previously presented) Organometallic complexes produced by the process comprising reacting:

- at least one strontium cation,
- sitosterol or a plant extract containing same,
- at least one mono-, one di- or one triglyceride corresponding to formula (I):



in which:

R<sub>1</sub> is an acyl moiety of a C14 to C24 fatty acid, saturated or not, linear or branched, a hydrogen atom, or a mono-, di- or tri- galactose or glucose,

-R<sub>2</sub> is an acyl moiety of a C2 to C18 fatty acid, linear or branched, saturated or not,

-R<sub>3</sub> is an acyl moiety of a C14 to C24 fatty acid, saturated or not, linear or branched, or a hydrogen atom.

Claim 2 (Previously presented) Complexes according to claim 1, wherein at least one of the groups R<sub>1</sub> or R<sub>3</sub> in formula (I) hereinabove includes an acyl moiety of oleic acid.

Claim 3 (Previously presented) Complexes according to either one of claims 1 or 2, in which  $R_2$  has an unsaturated bond.

Claim 4 (Original) Complexes according to either one of claims 1 or 2, in which  $R_2$  represents an acetyl group.

Claim 5 (Previously presented) Complexes according to claim 1, in which  $R_3$  in formula (I) represents the hydrogen atom.

Claim 6 (Previously presented) Complexes according to claim 1, in which the diglyceride is obtained by isolation from olive oil or an oil rich in oleic acid, or an oil fraction rich in oleic acid.

Claim 7 (Currently amended) Complexes according to claim 1, in which the strontium cation is provided by a strontium dichloride, strontium sulfates, or an organic strontium derivative, wherein said organic strontium derivative is strontium acetylacetonate or strontium ranelate ~~a dihalogenide an organic strontium derivative or a complex of strontium with organic solvents.~~

Claim 8 (Previously presented) A pharmaceutical composition comprising at least one complex defined in claim 1 and a pharmaceutically acceptable vehicle, excipient or support.

Claim 9 (Previously presented) A method for preparing a medicament intended for use as a regulator or stimulant of bone growth comprising combining the complexes of claim 1 with a pharmaceutically acceptable vehicle, excipient or support.

Claim 10 (Canceled)

Claim 11 (Previously presented) Dietetic products comprising at least one complex defined in claim 1.

Claim 12 (Canceled).

Claim 13 (Previously presented) Complexes according to claim 3, wherein the unsaturated bond represents an oleic acid or one of the double bond positional isomers cis-6, 7, 9, 11, 12 or 13, or one of the geometric isomers thereof.

Claim 14 (Currently amended) Complexes according to claim 7, wherein the strontium cation is provided by a strontium dichloride dihalogenide is a strontium dichloride, sulfate or hydrate.

Claim 15 (Currently amended) Complexes according to claim 7, wherein the strontium cation is provided by a strontium sulfate organic strontium derivative is an acetylacetonate or an alcoholate.

Claim 16 (Canceled)

Claim 17 (Withdrawn) A method of treating or preventing deficiencies or dysfunctions of bone growth comprising administering complexes of claim 1 to a subject.

Claim 18 (Withdrawn) The method of claim 17, wherein said deficiency or dysfunction of bone growth is osteoporosis.


Claim 19 (Withdrawn) A method of treating blood diseases involving a hematopoietic deficit comprising administering the complexes of claim 1 to a subject.

Claim 20 (Withdrawn) The method of claim 19, wherein complexes of claim 1 are used as an adjunct to anticancer therapies.

Claim 21 (Previously presented) A composition comprising:

- at least one strontium cation,
- sitosterol or a plant extract containing same,

- at least one mono-, one di- or one triglyceride corresponding to formula (I):



in which:

$R_1$  is an acyl moiety of a C14 to C24 fatty acid, saturated or not, linear or branched, a hydrogen atom, or a mono-, di- or tri- galactose or glucose,

$R_2$  is an acyl moiety of a C2 to C18 fatty acid, linear or branched, saturated or not,

$R_3$  is an acyl moiety of a C14 to C24 fatty acid, saturated or not, linear or branched, or a hydrogen atom.